

OUTPATIENT

OUTPATIENT	AMPI		AMPI/SULB		AZTREO		CEFAZOLIN		CEFEPIME		CEFOXTN		CEFTRIAX		CIPROFLX		GENT		MERO		NITRO		PIP/TAZO		TOBRA		TMP/SMX	
	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S
Acinetobacter baumannii complex ²			23	96					22	91			23	61	23	91	23	87	23	96			23	83	23	91	23	87
Citrobacter freundii					33	88			33	97			33	85	33	82	33	100	33	100	20 ²	85	33	88	33	94	33	88
Citrobacter koseri			110	95	110	99	110	95	110	100	110	98	110	99	110	96	110	100	110	100	94	48	110	96	110	100	110	98
Enterobacter cloacae					115	86			115	93			115	85	115	84	115	98	115	100	79	34	115	85	115	97	115	85
Escherichia coli	3128	40	3128	46	3128	87	3127	69	3127	87	3127	85	3127	86	3125	59	3127	87	3126	100	3010	97	3128	84	3125	85	3127	65
Klebsiella (Enterobacter) aerogenes					69	90			68	96			69	90	69	93	69	97	69	97	51	55	69	90	69	97	69	96
Klebsiella oxytoca			69	46	69	86	69	49	69	86	69	86	69	86	69	81	69	96	69	100	44	73	69	78	69	93	69	83
Klebsiella pneumoniae			701	67	699	83	701	72	700	83	701	78	700	83	700	77	701	93	700	100	634	51	701	78	701	90	701	77
Morganella morganii ²			84	31	83	93			83	99	84	77	84	94	84	70	84	88	84	100			84	94	84	90	84	76
Proteus mirabilis	375	73	375	81	375	93	375	3	375	94	374	93	375	94	374	83	375	76					375	93	375	81	375	87
Providencia stuartii ²			10	20	10	80			10	90	10	80	10	80	10	50			10	100			10	80			10	60
Serratia marcescens					46	100			46	100			46	93	46	98	46	98	46	100			46	96	46	59	32	100

	CEFTAZDM		LEVFLX		MINO		TMP/SMX	
	N	% S	N	% S	N	% S	N	% S
<i>Stenotrophomonas maltophilia</i> ²	21	43	21	71	21	76	21	100

	AMIK		AZTREO		CEFIPI		CIPROFLX		GENT		MERO		PIP/TAZO	
	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S
<i>Pseudomonas aeruginosa</i>	190	99	319	83	323	94	321	84	320	97	323	94	323	90

	AMPI		CEFTRIAX		CIPROFLX		TMP/SMX	
	N	% S	N	% S	N	% S	N	% S
<i>Salmonella</i> species	86	87	53	89	84	61	84	88

STAPHYLOCOCCUS ^A	CLINDA		OXA / CEF		GENT ^D		PEN G		TETRACYC		TMP/SMX		VANC	
	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S
<i>S. aureus</i> (MSSA)	752	76	752	100	752	97	752	0	752	92	751	92	751	100
<i>S. aureus</i> (MRSA) ^B	568	82	568	0	568	93	568	0	568	61	567	85	568	100
<i>S. epidermidis</i>	108	66	107	61	104	86	110	0	109	77			103	100
<i>S. haemolyticus</i> ²	12	25	12	25	12	42	12	0	12	50			16	100
<i>S. lugdunensis</i>	96	82	96	94	96	99	96	0	96	97	63	97	102	99
<i>S. saprophyticus</i> ²	24	83	24	92	24	100	24	0	24	88			22	100

- A.** All staphylococci may rapidly develop resistance during prolonged therapy with quinolones. Use with staphylococci is not recommended.
- B.** MRSA isolates with reduced susceptibility to daptomycin have been detected at Montefiore Campuses.
- C.** Oxacillin-resistant staphylococci are also resistant to all penicillins, cephalosporins, and carbapenems. Oxacillin-susceptible staphylococci are also susceptible to dicloxacillin, nafcillin, ampicillin-sulbactam, piperacillin-tazobactam, amoxicillin-clavulanic acid, cefazolin, cephalixin, cefotetan, ceftiofur, ceftriaxone, cefepime, and meropenem (as well as other penicillins, cephalosporins, and carbapenems that are non-formulary).
- D.** Gentamicin should not be used as single agent and only for synergy for treatment of staphylococcal infections.

NOTES

Box color:  intrinsic resistance

Less susceptible  More susceptible

Text color:

- > 10% increase in susceptibility from previous year
- > 10% decline in susceptibility from previous year

1. Minimum inhibitory concentrations (MIC) and interpretations are based on the CLSI standards and an advanced antibiotic expert system.
2. Percentages are not calculated for organisms with <10 isolates. For *N* of < 30 isolates, results may not be statistically relevant. Interpret with caution.

ENTEROCOCCUS URINE	AMPI		LEVOFLX		NITRO		TETRACYC		VANC	
	N	% S	N	% S	N	% S	N	% S	N	% S
<i>Enterococcus faecalis</i>	192	100	191	84	192	100	192	28	192	96
<i>Enterococcus faecium</i> ²	10	10	10	20	5	0	10	20	10	60

*Urine cultures with 10⁵ colonies of enterococci as a single organism have a routine susceptibility test. Infectious Diseases generally recommends susceptibility testing when patients do not respond to empiric therapy.

URINE	AMPI		AMPI/SULB		CEFAZOLIN		CIPROFLX		NITRO		TMP/SMX	
	N	% S	N	% S	N	% S	N	% S	N	% S	N	% S
<i>Escherichia coli</i>	3022	40	3022	46	3019	83	3019	60	3022	97	3021	66
<i>Klebsiella pneumoniae</i>			635	66	633	79	634	77	634	51	635	77
<i>Proteus mirabilis</i>	291	71	291	79	291	88	289	80			291	86

*For urine isolates, cefazolin results predict results for the oral agents cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, and cephalexin when used for therapy of **uncomplicated UTI** due to E. coli, K. pneumoniae, P. mirabilis.